Literature DB >> 7831534

Long-term follow-up of in situ carcinoma of the breast.

V Eusebi1, E Feudale, M P Foschini, A Micheli, A Conti, C Riva, S Di Palma, F Rilke.   

Abstract

Eighty cases of duct carcinoma in situ (DCIS) of the breast have been investigated by a cohort-retrospective study. These consisted of 8.5 per 1,000 of 9,446 breast biopsies originally diagnosed as benign, between 1964 and 1976, with a mean follow-up of 17.5 years. There were forty-one cases (51%) of DCIS of clinging type (CC); 30 cases (37.%) of CC associated with other types of DCIS; nine cases of DCIS other than CC two of which were DCIS of comedo-type. Invasive duct carcinoma (IDC) subsequently developed in 11 patients (14%), whereas DCIS recurred in 5 (6%). The recurrence was ipsilateral in 12 of these 16 patients. IDC appeared more frequently, with high statistical significance, when the lesion present in the original biopsy showed pleomorphic (P) nuclei (ie, poorly differentiated cyto-nuclear morphology). The Standardized Morbidity Ratio (SMR) was 8.0 (95% CI; 2.9-17.5) with the general population as reference. IDC that developed following a lesion displaying P nuclei also showed a statistically significantly more aggressive behavior. It is suggested that when cases of DCIS are followed-up for a considerable length of time, a two-wave pattern of aggressiveness becomes apparent. IDC that develops after a poorly differentiated DCIS leads to death more precociously than that appearing after other types of DCIS, especially those showing more bland nuclear cytology.

Entities:  

Mesh:

Year:  1994        PMID: 7831534

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  61 in total

1.  Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.

Authors:  C Van Poznak; S S Cross; M Saggese; C Hudis; K S Panageas; L Norton; R E Coleman; I Holen
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

2.  [Flat epithelial atypia].

Authors:  W Böcker; D Hungermann; J Tio; S Weigel; T Decker
Journal:  Pathologe       Date:  2009-02       Impact factor: 1.011

3.  Ductal Carcinoma in Situ: Clinical Perspective.

Authors:  Thorsten Kühn
Journal:  Breast Care (Basel)       Date:  2010-08-02       Impact factor: 2.860

4.  Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice.

Authors:  Amy Brock; Silva Krause; Hu Li; Marek Kowalski; Michael S Goldberg; James J Collins; Donald E Ingber
Journal:  Sci Transl Med       Date:  2014-01-01       Impact factor: 17.956

Review 5.  Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer?

Authors:  Gulisa Turashvili; Malcolm Hayes; Blake Gilks; Peter Watson; Samuel Aparicio
Journal:  Virchows Arch       Date:  2008-04-24       Impact factor: 4.064

6.  Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas.

Authors:  N Kapucuoglu; L Losi; V Eusebi
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

7.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

8.  Status of Intraductal Therapy for Ductal Carcinoma in Situ.

Authors:  Meghan Flanagan; Susan Love; E Shelley Hwang
Journal:  Curr Breast Cancer Rep       Date:  2010-05-06

9.  Columnar cell lesions and subsequent breast cancer risk: a nested case-control study.

Authors:  Sarah A Aroner; Laura C Collins; Stuart J Schnitt; James L Connolly; Graham A Colditz; Rulla M Tamimi
Journal:  Breast Cancer Res       Date:  2010-08-06       Impact factor: 6.466

10.  Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.

Authors:  Yunn-Yi Chen; Sandy DeVries; Joseph Anderson; Juan Lessing; Rebecca Swain; Koei Chin; Veronica Shim; Laura J Esserman; Frederic M Waldman; E Shelley Hwang
Journal:  BMC Cancer       Date:  2009-08-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.